Bearish markets test the mettle of every trader—but they also sharpen strategy and reveal hidden potential. Success lies in recognizing resistance zones, anticipating trend shifts, and enforcing disciplined risk controls like stop-losses and diversified holdings. Staying informed on macroeconomic developments—such as fiscal policy, global trade dynamics, and central bank signals—adds a crucial layer of foresight. Rather than fearing downturns, seasoned traders view them as setups for future gains. With patience, adaptability, and a clear-eyed strategy, every dip becomes a stepping stone toward long-term resilience.

Johnson & Johnson’s third quarter results show a company in transition but still performing well. Revenue rose 7% to $24 billion, with solid contributions from both Innovative Medicine and MedTech. The $240 million revenue beat and slight EPS beat suggest steady execution despite a challenging environment The Innovative Medicine segment continues to be the engine of growth, up 7% year over year. Oncology is clearly the standout, with Darzalex climbing 20% and Carvykti surging 81% a strong sign that J&J’s bets in cell therapy are paying off. The main drag was Immunology, where a 10% decline reflected heavy biosimilar pressure on Stelara. Tremfya’s 40% growth helped, but not enough to offset Stelara’s 42% drop. MedTech also delivered, up nearly 7% to $8.4 billion. Cardiovascular devices were a highlight, thanks in part to acquisitions like Abiomed and Shockwave. The segment looks increasingly like a reliable growth contributor, not just a supporting player. The headline move, though, is J&J’s decision to spin off its orthopedics division, DePuy Synthes, a $9.2 billion business that’s grown more slowly than the rest of the company. The separation, planned within the next 18 to 24 months, signals a clear shift toward faster-growing and higher-margin areas such as oncology and medtech innovation. With the full year revenue outlook nudged higher and EPS guidance reaffirmed, management is striking a confident tone. The company still faces headwinds particularly Stelara’s patent erosion and broader political scrutiny on drug pricing but its strategy is clear, focus resources where it can lead and divest where it can’t. The result should be a leaner, more growth-oriented J&J over the next few years..

Bear Call Spread Sell 195 Call strike and Buy 200 Call Strike, Exp: Nov 28 (45 DTE) for no less than $1.55 Trade has about 67% probability of profit Credit received = $155 BP Effect = $345 Max Loss = (5 - 1.55) * 100 = $345 Breakeven = 195 + 1.55 = $196.55 Percentage return: (155 / 345) * 100 =44.928% JNJ has seen a significant rise and it at ATH, RSI indicator also shows JNJ being overbought Trade is just for educational purposes and willing to

JNJ – Financial Performance & SWOT Analysis JNJ Undervalued with Strong Fundamentals Pharma Giant? (1/9) Good morning, folks! JNJ is steady 📈, at $ 191.08 up 35.31% YTD per October 10, 2025. Q2 revenue shakes up this pharma play , let’s dive in! 📊🔥 Tag a friend who needs this investing hack! (2/9) – PRICE PERFORMANCE • Last week: $ 191.08, up from $ 189.69 close 📈 • YTD 2025: up 35.31%, outpacing S&P 500 🔄 • Q2 2025: revenue up to $23.74B 🚀 This pharma stock’s volatility, earnings beats pop! 💥 (3/9) – MARKET POSITION • Market Cap: $ 460.19B, industry leader 🏆 • Avg Volume: 8.67M shares, high liquidity 💧 • Trend: P/E 19.1x below fair ratio 👑 This asset’s dominance, holding tight! 🔒 (4/9) – KEY DEVELOPMENTS • Q2 earnings: revenue $23.74B, EPS $2.77 beat 💰 • Price target: Goldman Sachs to $212 🏭 • Sentiment: undervalued on valuation models 📈 This pharma move, stable push! ⚡ (5/9) – RISKS IN FOCUS • Regulations: pharma sector impacts ⚠️ • Competition: rising from peers 🆚 • Volatility: beta 0.39 swings 📉 This ticker’s exposure, watch these twists! ⚠️🔄 (6/9) – SWOT: STRENGTHS • Earnings stability (consistent.): value driver 🌟 • Diversified portfolio (healthcare.): resilience 🤖 • Dividend yield (strong.): investor appeal 👥 This asset’s edge, built tough! 💪 (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES • Weaknesses: litigation risks, P/E adjustments ⚖️ • Opportunities: growth in medtech, undervaluation 🌍 Can this ticker beat the odds? 🎲 Reply with your take! (8/9) – POLL TIME! JNJ’s $ 191.08 value, your vibe? • Bullish: $210+ soon, earnings beats 📈🚀 • Neutral: Steady, risks balanced ⚖️🛡️ • Bearish: $180 looms, regulation hits 📉⚠️ Chime in below! 💬 Tag a friend for this poll! (9/9) – FINAL TAKEAWAY JNJ’s $ 191.08 stance shows resilience 💪, fundamentals fuel it ⚡. Risks bite 🦈, yet dips are DCA gold 💎. We grab ‘em low, climb like pros! Gem or bust? not advice, just our spin! #JNJ #Investing #Markets #Trading #Finance #ETF #Commodities #DCA #Trends JNJ is potentially undervalued as of October 10, 2025, at $ 191.08, up 35.31% YTD per TradingView. Q2 revenue shapes its path in the pharma space. Here’s a factual financial and strategic breakdown. **Financial Performance** Price Movement: YTD at $ 191.08, up 35.31%. Broader period shows gains amid market rally. Q2 adds upside, with revenue $23.74B. Volume & Market Cap: Avg volume 8.67M shares. Market cap at $ 460.19B. Key Metric: Trailing P/E 20.46, forward P/E 16.42. **SWOT Analysis** Strengths: - Diversified healthcare portfolio. - Strong earnings and dividend yield. - Market leadership in pharma. Weaknesses: - Litigation and regulatory risks. - P/E adjustments for value. - Exposure to economic cycles. Opportunities: - Growth in medtech and pharma. - Undervaluation per models. - Upcoming earnings potential. Threats: - Intense competition. - Market corrections. - Supply chain issues. **JNJ vs. SPY: Key Comparisons** | Aspect | JNJ | SPY | |--------|------|-----| | Purpose & Scope | Pharma and healthcare focus | Broad market index tracking | | Dynamics | Beta 0.39 volatility vs. lower 1.00 | Steady benchmark | | Market Position | Up 35.31% YTD, undervalued P/E vs. S&P gains | Stable exposure | **Investor Considerations: DCA** Dollar Cost Averaging: JNJ’s volatility suits dip-buying. At $ 191.08, $10,000 buys ~52 shares; a 10% dip to $ 172 nets ~58 shares. **Outlook & Risks** JNJ’s $ 191.08 position shows stable edge, with revenue growth. Regulations loom, yet dip grabs turn volatility into gains. Growth or dividends could sway it, but time’s our edge. Gem or fade? Depends on healthcare demand.

Enter: NYSE:JNJ OCT 31 2025 $190 CALLS Buy in Price: $4.15 - $4.35 Take Profit: $10.13 Stop Bleeding: $3.65 ROI Potential: 144% Exit Within: 339 Minutes

This short trade is based on the idea that JNJ's stock price has extended beyond a long-term upward channel, suggesting a high-probability mean reversion or correction back toward the established trendline. The chart suggests a bearish divergence or a temporary blow-off top scenario. The price has accelerated sharply, poking above the main channel (orange line). The strategy capitalizes on the expectation that this extended move will fail, leading to a strong retracement to "reset" the stock back into its longer-term average trend. Macro Thesis: The bearish case argues that JNJ's stock price, which has historically commanded a premium for its stability, is vulnerable to a correction as the market fully prices in the combined near-term negative catalysts: the immediate drag from Stelara's LOE, the ongoing financial uncertainty of the talc lawsuits, and the general sector pressure from US drug pricing reform. This confluence of factors makes the stock less of a "safe haven" and more susceptible to the technical correction suggested by your chart. Trade Idea: Initial Short Entry $192.20 (Light Red Arrow) This price sits right at the upper boundary of the short-term rising channel (pink line) and may represent the first sign of exhausted momentum following a sharp run-up. Initiating a light position here hedges against a potential immediate drop. Add to Short $198.11 (Dark Red Arrow) This price is at or near the upper boundary of the long-term channel (orange line). This level is the key resistance for the entire price structure. If the price reaches here and fails to break out convincingly, it's a strong signal of a major rejection and provides a high-confidence level to increase the short position size. Target Exit (Take Profit) $172.07 (Green Arrow) This target is set near the midpoint of the current rising channel (dark red line). This level represents a high-probability support zone and the natural point for the stock to revert to after correcting from an overbought or extended state. This offers a potential return of 10.5% to 13.4% from the two entry points. Disclaimer: This analysis is based solely on the technical indicators and levels presented in the provided image and is not financial advice. The stock market is inherently unpredictable, and you should always conduct your own research before making investment decisions.

- Johnson & Johnson broke key resistance level 180.00 - Likely to rise to resistance level 190.00 Johnson & Johnson recently broke sharply above the key resistance level 180.00 (which stopped the previous minor impulse wave 3 at the end of August). The breakout of the resistance level 180.00 accelerated the active impulse wave 5 of the intermediate impulse wave (3) from April. Given the predominant daily uptrend, Johnson & Johnson can be expected to rise to the next resistance level 190.00, target price for the completion of the active impulse wave 5.

NYSE:JNJ has recently shown a bullish chart pattern on the 3-month timeframe, which in my view suggests the stock may be aiming for new all-time highs. That makes it, in my opinion, a good stock to hold in a portfolio over the next 2 to 3 months. This is not financial advice.

Johnson & Johnson has been in a strong uptrend, with buyers consistently driving price higher. After the impulsive rally, price consolidated into a downward-sloping flag, where sellers tried to take control but failed to push lower. Buyers then stepped back in, breaking out of the flag with strength. That’s our long entry signal, confirming buyers are firmly in control and positioning for continuation toward the next target around 190. The fundamentals for J&J are mostly supportive: strong earnings, raised guidance, strategic acquisition add weight to bullish bias and the technical outlook. But stay alert to catalysts that could turn sentiment fast.

#JNJ 26.9.2025 US ep - 178.78 sl - 175.03 (2.11%) tp - 186.38 (4.23%) rrr - 2X